Upstream Bio, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Upstream Bio, Inc. | UPB - NASDAQ |
$15.00-$17.00 | $17.00 | $21.50 | 15 million | 10/11/2024 |
| JP Morgan, TD Cowen, Piper Sandler, William Blair | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2024-09-18 Terms Added 2024-10-07 | ||||||
Upstream Bio, Inc. Quote & Chart - Click for current quote - UPB
IPO Boutique aggregates information on public companies and private companies, such as "UPB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Upstream Bio, Inc. (adapted from Upstream Bio, Inc. prospectus):
They are a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "UPB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.